GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (NAS:VERU) » Definitions » Ending Cash Position

Veru (VERU) Ending Cash Position : $29.15 Mil (As of Jun. 2024)


View and export this data going back to 1990. Start your Free Trial

What is Veru Ending Cash Position?

Veru's Ending Cash Position for the quarter that ended in Jun. 2024 was $29.15 Mil.

Veru's quarterly Ending Cash Position declined from Dec. 2023 ($40.58 Mil) to Mar. 2024 ($34.74 Mil) and declined from Mar. 2024 ($34.74 Mil) to Jun. 2024 ($29.15 Mil).

Veru's annual Ending Cash Position declined from Sep. 2021 ($122.36 Mil) to Sep. 2022 ($80.19 Mil) and declined from Sep. 2022 ($80.19 Mil) to Sep. 2023 ($9.63 Mil).

Veru Ending Cash Position Historical Data

The historical data trend for Veru's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Ending Cash Position Chart

Veru Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.30 13.59 122.36 80.19 9.63

Veru Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.21 9.63 40.58 34.74 29.15

Veru Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Veru's Ending Cash Position for the fiscal year that ended in Sep. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=80.191+-70.566
=9.63

Veru's Ending Cash Position for the quarter that ended in Jun. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=34.739+-5.588
=29.15

Veru Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Veru's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Veru Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (NAS:VERU) » Definitions » Ending Cash Position
Comparable Companies
TLSA NVCT IMUX MIST LPTX GUTS RGLS ASMB IPSC ANIX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
FMW:Germany FMW:Germany
Address
2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Website
https://www.verupharma.com
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
Executives
Harry Fisch director, 10 percent owner 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Mitchell Shuster Steiner director, 10 percent owner, officer: President and CEO 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
K Gary Barnette officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Mario Eisenberger director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Lucy Lu director THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Grace Hyun director 48 NW 25TH STREET, SUITE 102, MIAMI FL 33127
Michele Greco officer: VP and CFO 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60654
Jesus Socorro director 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Todd Charles T Jr officer: CEO of FHC Division 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michael L Rankowitz director 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Robert Getzenberg officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elgar Peerschke director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Daniel Haines officer: CFO and COO 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
David R Bethune director THE FEMALE HEALTH COMPANY, 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60610
O B Parrish director, officer: Chairman/Chief Exec. Officer